

Please try another search
By Lawrence White and Julie Zhu
LONDON/HONG KONG (Reuters) - Stocks, oil and risk currencies gained on Tuesday as the formal go-ahead for U.S. President-elect Joe Biden to begin his transition burnished a November already boosted by COVID-19 vaccines.
European markets tracked gains in Asian and U.S. equities, with the broad-based STOXX 600 index opening 0.8% higher and Brent crude climbing to its highest level since March at $46.38 a barrel. Safe haven assets such as gold fell.
After weeks of legal challenges to the election results, U.S. General Services Administration chief Emily Murphy wrote to Biden on Monday informing him the formal hand-over process could begin.
President Donald Trump tweeted that he had told his team "do what needs to be done with regard to initial protocols", an indication he was moving toward a transition.
"Markets have been constrained by very high levels of uncertainty on the U.S. political front and around vaccines for weeks, so with those two going away investors are considering the prospect of a return to normality in 2021," said Emmanuel Cau, head of European equity strategy at Barclays (LON:BARC).
Reports that Biden plans to nominate former Federal Reserve Chair Janet Yellen to become the next Treasury Secretary further boosted U.S. stocks on expectations she would pursue more conventional policies than the outgoing Steven Mnuchin.
Futures for the S&P 500 rose 1.2% in early European trading hours and putting the 49-country MSCI world stocks index on course to set a new record high later.
Japan's Nikkei jumped 2.5% to its highest level since May 1991 overnight, with energy, real estate and financial shares leading the advance.
Asia-Pacific shares outside Japan had ticked up 0.4%. Australia's S&P/ASX 200 was 1.26% stronger, touching its highest level in almost nine months, with energy stocks leading the pack there.
Seoul's Kospi was 0.6% higher as was Hong Kong's Hang Seng which rose 0.4%. China blue-chips were an outlier however, edging down 0.6%, as investors booked profits following recent strong gains.
(Graphic: Global markets enjoying November reign https://fingfx.thomsonreuters.com/gfx/mkt/azgpozyqgvd/24-11%20assets.jpg)
Some analysts say a Biden presidency, which could mean more negotiation room for Washington and Beijing, would not make a big difference for China's equities market, as they expected little change in broad U.S. policy toward China.
The progress made on COVID-19 vaccines, which had underpinned Wall Street overnight, helped keep risk appetite elevated as it boosted optimism about a quicker revival for the global economy.
AstraZeneca (NASDAQ:AZN) and Oxford University had said on Monday that their COVID-19 vaccine, which is cheaper to make, easier to distribute and faster to scale-up than its rivals, could be as much as 90% effective.
RISK ON
The New Zealand dollar was among the currency gainers, rising as much as 0.9% to a two-year high of $0.6985 as its central bank said house prices, which have been storming higher this year, could be included in its inflation basket.
The euro was gaining towards $1.19 again and the dollar index, which tracks the greenback against a basket of six major rivals, nudged down to 92.235.
Also spurred on by the vaccine hopes, oil reached levels not seen since before the coronavirus began to spread rapidly in March and decimated demand.
Brent crude futures rose 45 cents, or 1%, to $46.51 a barrel to add to a more than 20% surge this month, while U.S. West Texas Intermediate crude added 46 cents, or 1.1%, to $43.52.
"Progress on developing and distributing a vaccine de-risks the path back to normal for oil markets," said Stephen Innes, chief global markets strategist at financial services firm Axi.
In the bond markets, the yield on the benchmark 10-year notes rose slightly to 0.87% as did those on most European government bonds. Germany's 10-year yield was up 1 basis point to -0.57% in early trade.
Gold continued to lose its shine too, falling to $1,826.3 an ounce having now dropped 10% this month.
By Michael Erman NEW YORK (Reuters) -U.S. health regulators will not require companies to submit new clinical trial data on COVID-19 vaccines that target the now dominant BA.4 and...
By Katanga Johnson WASHINGTON (Reuters) - A U.S. Supreme Court decision to curb the Environmental Protection Agency's power to regulate greenhouse gas emissions may be bad news...
By Katie Paul
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.